DefiniGEN

🌟 Revolutionize Your Research with DefiniGEN’s Cell Products! 🌟 At DefiniGEN, we provide highly characterized, mature iPSC-derived wild-type and disease models to support your cutting-edge research. Our product range includes: 🔬 Wild-Type & Disease Model Hepatocytes for conditions such as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alpha-1 Antitrypsin Deficiency (A1ATD), Wilson’s Disease, PFIC2 and Urea Cycle disorders. 🔬 World’s first commercially available iPSC-derived Hepatic Stellates. 🔬 Intestinal Organoids. These models are designed to accelerate breakthroughs in drug development, disease modeling, toxicology investigations and efficacy screening by overcoming the drawbacks of primary, animal and immortalized cell models. 📢 Explore the full range here: https://lnkd.in/ey27Q2Uk #DiseaseModels #MASLD #A1ATD #hepatocytes #stemcells #iPSCs #Organoids #BiomedicalResearch #CellModels #drugdiscovery #liverdisease #nafld #mafld #nasld

🚀 New Blog Alert: Advancing Liver Research with iPSC-Derived Hepatic Stellate Cells 🚀 At DefiniGEN, we are pushing the boundaries of liver research with our cutting-edge iPSC-derived Hepatic Stellate Cells:  Opti-HSC. In our latest blog post, we dive deep into how Opti-HSC are transforming understanding of liver biology and providing new avenues for drug discovery and disease research. 🔬 Why it matters: -First of its kind: Opti-HSC are the first commercially available iPSC-derived hepatic stellates on the market for researchers looking to model liver diseases or screen their compounds for drug discovery. -Accelerated drug development: Overcome the drawbacks associated with traditional models such as primary and immortalized cell models such as donor variation and lack of scalability -Accurate Disease Modeling: Opti-HSC express crucial activation markers, enabling precise modeling of hepatic fibrosis that closely mirrors human disease states. Discover how this innovative model could reshape and accelerate your liver research! 👉 Read the full blog here: https://lnkd.in/e9ccUyEY #LiverResearch #StemCells #iPSC #HepaticStellateCells #DrugDiscovery #FibrosisResearch #DiseaseModeling #ResearchAndDevelopment

We are thrilled to announce that our Director of Operations, Celine Gomez, accepted the Green Impact Silver Award, which was awarded to #DefiniGEN by Students Organising for Sustainability (SOS-UK). Green Impact is a United Nations award-winning program designed to support environmentally and socially sustainable practice in organizations based in the UK. By committing to the scheme and completing a significant amount of the actions, we have reduced our waste output and carbon footprint whilst also increasing how much we recycle and reuse. A big thank you to all of our team for making these changes and to Students Organizing for Sustainability for bestowing this award. A special thank you to Celine, Gemma Gatti, Jenny Shepperd and Magdalena Łukasiak for all their efforts this year to help us achieve this award. #greenimpact #environment #sustainability #climatechange #award

🚨 New scientific article alert! 🚨 Our new paper is available to read and download today: “Development of optimised human iPSC-derived hepatocytes with improved liver 2 function for in vitro metabolic disease modelling and toxicity studies” Liver diseases are on the rise globally, and traditional models like primary human hepatocytes (PHH) and hepatocellular carcinoma cells have significant limitations in drug development. These include issues with scaling, rapid loss of function, and tumorigenic origins. Current iPSC-derived models also fall short in mimicking full hepatocyte functionality. 💡 Our latest breakthrough: Optimized iPSC-derived Hepatocytes: Opti-HEP By fine-tuning iPSC differentiation protocols, we’ve developed Opti-HEP—iPSC-derived hepatocytes that show improved metabolic functionality for disease modeling, efficacy screening and toxicity screening. Key Findings: - Liver Maturity: Opti-HEP cells expressed liver-specific markers and exhibited functional urea synthesis, gluconeogenesis, and CYP450 activity similar to primary hepatocytes (PHH). -Predicting Drug-Induced Liver Injury (DILI): Opti-HEP accurately predicted DILI for 7 drugs with known liver toxicity profiles. -Inherited Disease Modeling: Using CRISPR, we generated disease models for conditions like Ornithine Transcarbamylase Deficiency and Progressive Familial Intrahepatic Cholestasis Type 2, recapitulating key disease features such as impaired urea secretion and bile acid transport. 📩 Contact us to learn more about how Opti-HEP can support your research!: https://lnkd.in/e9p-BzBi Check out the paper here: https://lnkd.in/eMu7CKTB #LiverDisease #DrugDiscovery #iPSC #Hepatocytes #DiseaseModeling #Biotech #CellTherapy #Hepatotoxicity #DefiniGEN #PFIC2 #OTC #Toxicology

Missed Our Live Webinar on iPSC-Derived Liver Systems for MASLD Modeling and Therapy Screening? 🎥 You can watch the Webinar on demand now! 🎥   Our expert-led webinar dives deep into how induced pluripotent stem cell-derived hepatocyte models are transforming the way we assess drug safety, toxicity, and efficacy in preclinical research. Hosted by Genetic Engineering & Biotechnology News, this webinar provides invaluable insights into:   🔬 Why traditional MASLD models are insufficient: Understand the limitations of primary hepatocytes, animal models, and immortalized cell lines. 🌍 How can Opti-HEP help?: Learn how our iPSC-derived hepatocytes- Opti-HEP, can offer more predictive, ethical, and scalable solutions for your drug safety assessments. ⚙️Accelerating your drug development pipeline: Discover how our iPSC-derived MASLD disease model can de-risk drug discovery by providing you with a predictive, human-relevant model, bridging gaps where animal and primary cell models fall short.   Whether you’re a pharmaceutical researcher, toxicologist, or part of a biotech, this webinar will equip you with the knowledge you need to improve the accuracy and efficiency of your drug discovery process.   👉 Watch the webinar now: https://lnkd.in/eCsaPydS   #Webinar #StemCells #OptiHEP #PreclinicalResearch #DrugDevelopment #DefiniGEN #liver #MASLD #hepatocytes #liverdisease #nafld #nasld #mafld 

French Lewis, III is attending Advanced Therapies today in Philadelphia and is excited to talk to you about your pre-clinical research! French will be available to discuss how our toxicology screening and efficacy services are helping researchers improve their therapeutic discovery efforts and bring safer treatments to market quicker, using our iPSC-derived hepatocytes, Opti-HEP. 💬 Interested in learning more? Drop by and connect with French at Advanced Therapeutics or reach out directly to schedule a call with one of our experts here: 🔗 https://lnkd.in/e9p-BzBi #AdvancedTherapeutics #DrugDiscovery #GeneTherapy #CellTherapy #Biotech #Pharma #HumanModels #Toxicology #StemCells #DefiniGEN #Innovation #LifeSciences #RegulatoryScience

🚨 The Current State of Toxicology Screening: Why It's Time for a Change🚨   Traditional toxicology screening models, while essential, often fall short in key areas:   1) Animal Testing: Ethical concerns and regulatory limitations are growing. 2) Lack of Predictive Accuracy: Many in vitro models don’t reflect human cellular responses accurately, leading to costly late-stage failures. 3) Time and Resource Intensive: Long testing cycles slow down drug development and increase costs. DefiniGEN is here to change that. Our cutting-edge iPSC-derived hepatocyte models are revolutionizing toxicology screening by offering: ✅ More Accurate Human-Relevant Data: No more relying on animal models or outdated in vitro tests that don't replicate human physiology. ✅ Faster Turnaround Times – Quickly assess toxicity and streamline your drug development process. ✅ Ethical and Regulatory Alignment – We offer solutions that align with the growing demand for ethical testing and adhere to evolving regulatory guidelines.   Learn how our state-of-the-art toxicology screening platforms can reduce risk and accelerate your projects with reliable, human-based models.   🔗 Discover More: https://lnkd.in/ePdv2G25   #Toxicology #Pharmaceuticals #DrugDevelopment #StemCells #LifeSciences #DefiniGEN #CellTherapy #EthicalTesting #Hepatocytes #liverdisease

If you missed Nicholas Clare’s talk about our MASLD model at ELRIG Advancing Human-Centered Research in Metabolic Disease through Innovative Tools Forum yesterday, have no fear! Because you can learn all about the iPSC-derived MASLD model from our interview with Head of R&D, Nikolaos Nikolaou, DPhil, here: https://lnkd.in/eyctGEVW In this interview Nik explains what the drawbacks to current models used to study MASH/MASLD and how DefiniGEN’s iPSC-derived MASLD model can overcome these drawbacks. Don’t settle for an inferior model, check out our MASLD model today: https://lnkd.in/es7jHVYg #masld #mafld #nasld #nafld #liverdisease #hepatocytes #stemcells #iPSCs

ELRIG UK's Advancing Human-Centred Research In Metabolic Disease Through Innovative Tools Forum is in full swing! If you're attending be sure to check out Nicholas Clare's talk: "Developing iPSC-Derived Liver Systems for MASLD" In the auditorium at 15.15 today! (Be sure to check out our booth for free chocolates too) #masld #elrig #liver #hepatocyte #nasld #nafld #mafld #liverdisease

#Waistcoat